Sprycel News and Research

RSS
On June 28, 2006, the FDA granted accelerated approval of SPRYCEL for the treatment of adults in all three phases of CML (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec. The FDA also granted full approval of SPRYCEL for the treatment of adults with Ph+ ALL with resistance or intolerance to prior therapy. SPRYCEL is the first approved oral tyrosine kinase inhibitor that, at nanomolar concentrations, inhibits BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß kinases. The active ingredient of SPRYCEL is dasatinib. Dasatinib reduces the activity of one or more proteins responsible for the uncontrolled growth of the leukemia cells of patients with CML or Ph+ ALL.
CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug

CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

Sprycel holds hope for treating Src dependent ovarian cancer

Sprycel holds hope for treating Src dependent ovarian cancer

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

FDA grants full approval for Sprycel (dasatinib) for chronic myeloid leukemia

FDA grants full approval for Sprycel (dasatinib) for chronic myeloid leukemia

Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers

Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers

Chronic myelogenous leukemia patient survey shows that side effects are a serious issue

Chronic myelogenous leukemia patient survey shows that side effects are a serious issue

Researcher develops method for early detection of leukemia relapse

Researcher develops method for early detection of leukemia relapse

Experimental drug SGX393 offers new approach to help control drug resistance in leukemia

Experimental drug SGX393 offers new approach to help control drug resistance in leukemia

Bosutinib safe, effective for chronic myelogenous leukemia

Bosutinib safe, effective for chronic myelogenous leukemia

Data confirm Dasatinib's effectiveness in resistant chronic myelogenous leukemia

Data confirm Dasatinib's effectiveness in resistant chronic myelogenous leukemia

New drug candidate knocks out resistant form of chronic myeloid leukemia

New drug candidate knocks out resistant form of chronic myeloid leukemia

New role for miRNA in leukemia discovered

New role for miRNA in leukemia discovered

Nilotinib and Dasatinib show promise as therapy for chronic myelogenous leukemia

Nilotinib and Dasatinib show promise as therapy for chronic myelogenous leukemia

Tasigna gets the green light in the U.S. to treat Chronic Myeloid Leukemia

Tasigna gets the green light in the U.S. to treat Chronic Myeloid Leukemia

Fingolimod shows promise in 2 lethal leukemias

Fingolimod shows promise in 2 lethal leukemias

Combination of drugs might decrease the chance of chronic myeloid leukemia returning

Combination of drugs might decrease the chance of chronic myeloid leukemia returning

Dasatinib shows promise as first treatment for chronic myelogenous leukemia

Dasatinib shows promise as first treatment for chronic myelogenous leukemia